166 related articles for article (PubMed ID: 15490430)
1. Bootstrap confidence intervals for medical costs with censored observations.
Jiang H; Zhou XH
Stat Med; 2004 Nov; 23(21):3365-76. PubMed ID: 15490430
[TBL] [Abstract][Full Text] [Related]
2. Empirical likelihood-based confidence intervals for mean medical cost with censored data.
Jeyarajah J; Qin G
Stat Med; 2017 Nov; 36(25):4061-4070. PubMed ID: 28744877
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
Brown RE; Henderson RA; Koster D; Hutton J; Simoons ML
Eur Heart J; 2002 Jan; 23(1):50-8. PubMed ID: 11741362
[TBL] [Abstract][Full Text] [Related]
4. A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored.
Blackhouse G; Briggs AH; O'Brien BJ
Med Decis Making; 2002; 22(2):173-7. PubMed ID: 11958499
[TBL] [Abstract][Full Text] [Related]
5. Use of the bootstrap in analysing cost data from cluster randomised trials: some simulation results.
Flynn TN; Peters TJ
BMC Health Serv Res; 2004 Nov; 4(1):33. PubMed ID: 15550169
[TBL] [Abstract][Full Text] [Related]
6. A study on confidence intervals for incremental cost-effectiveness ratios.
Wang H; Zhao H
Biom J; 2008 Aug; 50(4):505-14. PubMed ID: 18663759
[TBL] [Abstract][Full Text] [Related]
7. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
8. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
Szucs TD; Schwenkglenks M; Berger K; Karsch K
Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
[TBL] [Abstract][Full Text] [Related]
9. A two-part model for censored medical cost data.
Tian L; Huang J
Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
[TBL] [Abstract][Full Text] [Related]
10. Accurate confidence limits for quantiles under random censoring.
Strawderman RL; Parzen MI; Wells MT
Biometrics; 1997 Dec; 53(4):1399-415. PubMed ID: 9423256
[TBL] [Abstract][Full Text] [Related]
11. The effect of outliers on confidence interval procedures for cost-effectiveness ratios.
Indurkhya A; Gardiner JC; Luo Z
Stat Med; 2001 May 15-30; 20(9-10):1469-77. PubMed ID: 11343367
[TBL] [Abstract][Full Text] [Related]
12. Empirical likelihood-based inferences for median medical cost regression models with censored data.
Wei G; Qin G
J Biopharm Stat; 2021 Mar; 31(2):216-232. PubMed ID: 32951509
[TBL] [Abstract][Full Text] [Related]
13. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
Zhang Z; Foster JK; Kolm P; Jurkovitz CT; Parker KM; Murrah NV; Anderson GT; Douglas JS; Weintraub WS
Am Heart J; 2006 Oct; 152(4):770-6. PubMed ID: 16996857
[TBL] [Abstract][Full Text] [Related]
14. Estimating medical costs from incomplete follow-up data.
Lin DY; Feuer EJ; Etzioni R; Wax Y
Biometrics; 1997 Jun; 53(2):419-34. PubMed ID: 9192444
[TBL] [Abstract][Full Text] [Related]
15. Average cost-effectiveness ratio with censored data.
Bang H; Zhao H
J Biopharm Stat; 2012; 22(2):401-15. PubMed ID: 22251182
[TBL] [Abstract][Full Text] [Related]
16. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
[TBL] [Abstract][Full Text] [Related]
17. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation.
Briggs AH; Mooney CZ; Wonderling DE
Stat Med; 1999 Dec; 18(23):3245-62. PubMed ID: 10602149
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
Lindgren P; Jönsson B; Yusuf S
J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
[TBL] [Abstract][Full Text] [Related]
19. Bootstrap confidence intervals for the mode of the hazard function.
Mazucheli J; Barros EA; Achcar JA
Comput Methods Programs Biomed; 2005 Jul; 79(1):39-47. PubMed ID: 15955591
[TBL] [Abstract][Full Text] [Related]
20. Influence function-based empirical likelihood for inference of quantile medical costs with censored data.
Jeyarajah J; Wei G; Qin G
Stat Methods Med Res; 2020 Jul; 29(7):1913-1934. PubMed ID: 31595834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
